Flinders University Flinders Academic Commons
 

Flinders Academic Commons >
Research Publications >
ERA 2010 >
07 - Biomedical and Clinical Research >
1108 - Medical Microbiology >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2328/10687

Title: Outcomes of patients with melioidosis treated with meropenem
Authors: Fisher, Dale
Stephens, Dianne Patricia
Jacups, Susan P
Anstey, Nicholas Mark
Cheng, Allen C
Currie, Bart John
Issue Date: 2004
Citation: Cheng, A., Fisher, D., Anstey, N.M., Stephens, D.P., Jacups, S.P., & Currie, B.J., 2004. Outcomes of patients with melioidosis treated with meropenem. Antimicrobial Agents and Chemotherapy, 48(5), 1763-1765.
Abstract: Melioidosis, an infection due to Burkholderia pseudomallei, is endemic in southeast Asia and northern Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (n 153) despite a deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenemtreated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We conclude that meropenem (1 g or 25 mg/kg every 8 h intravenously for >14 days) is an alternative to ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with improved outcomes in patients with severe sepsis associated with melioidosis.
URI: http://hdl.handle.net/2328/10687
ISSN: 0066-4804
Appears in Collections:1108 - Medical Microbiology

Files in This Item:

File Description SizeFormat
Cheng Outcomes.pdf222.84 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback